ERYTECH Pharma S.A. (NASDAQ:ERYP – Get Rating) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 38,400 shares, a drop of 5.4% from the February 13th total of 40,600 shares. Based on an average daily volume of 51,000 shares, the short-interest ratio is currently 0.8 days.
Hedge Funds Weigh In On ERYTECH Pharma
An institutional investor recently bought a new position in ERYTECH Pharma stock. Vanguard Personalized Indexing Management LLC acquired a new position in ERYTECH Pharma S.A. (NASDAQ:ERYP – Get Rating) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 95,268 shares of the company’s stock, valued at approximately $107,000. Vanguard Personalized Indexing Management LLC owned approximately 0.31% of ERYTECH Pharma as of its most recent filing with the Securities and Exchange Commission. 4.79% of the stock is currently owned by institutional investors and hedge funds.
ERYTECH Pharma Stock Performance
NASDAQ ERYP opened at $0.72 on Friday. The company has a 50 day moving average of $0.77 and a 200-day moving average of $0.67. ERYTECH Pharma has a 1-year low of $0.30 and a 1-year high of $2.18.
About ERYTECH Pharma
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.
- Get a free copy of the StockNews.com research report on ERYTECH Pharma (ERYP)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for ERYTECH Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ERYTECH Pharma and related companies with MarketBeat.com's FREE daily email newsletter.